Fritextsökning
Innehållstyper
-
Grönt ljus för Gesyntas endometriosstudie i Storbritannien – ”Ett stort steg”
Gesynta Pharma har fått klartecken i Storbritannien för att inleda en fas II-studie med sin läkemedelskandidat inom endometrios.
-
Pneumatics Makes a Technological Leap with Piezo
The first high-precision proportional valve terminal VTEP opens up new application areas
-
Lund University’s record-breaking recruitment – attracting researchers from around the world
The Swedish university is launching its largest international recruitment effort ever, aiming to hire 25 researchers globally, including several in the medical field.
-
Wegovy slog Mounjaro i studie om hjärtinfarkt
Under söndagen presenterade Novo Nordisk ny studiedata som pekar på att Wegovy kan minska risken för allvarliga kardiovaskulära händelser mer än Eli Lillys konk...
-
Join our measuringhero Jay on the innovation tour
Experience our latest innovation from the Control fair.
-
Try arivis for free
30-day free trial offers a number of benefits.
-
Webinar: Automate your processes
Free ZEISS webinar on January 30th, 2025.
-
FDA’s new CSA guidance: transforming software validation for production and quality systems
FDA’s final guidance on Computer Software Assurance (CSA) for Production and Quality System Software marks a significant modernization of software validation practices.
-
Introducing ZEISS arivis Pro 4.2
Your solution for advanced image analysis and visualization.
-
Introducing ZEISS arivis Pro 4.2
ZEISS arivis software enhances custom microscopy image analysis.
-
First preterm infants study – a vital step for Neola
After years of developing an advanced lung monitoring system, Neola Medical has received some delightful news: permission to start its first clinical study on p...
-
New features in ZEISS CALYPSO 2024
ZEISS CALYPSO is your universal software for dimensional metrology applications.
-
Anna Törner: ”Varför inte slå till på en ADHD-diagnos till kampanjpris?”
”Det är självklart positivt att neuropsykiatriska diagnoser inte upplevs som stigmatiserande, men just när det gäller ADHD kan jag inte låta bli att undra om de...
-
Recipharm ingår samarbete med global koncern
Recipharm ingår ett strategiskt samarbete med den globala franska koncernen Product Life Group (PLG).
-
Billion-Dollar Deal Sends BioArctic Soaring
Swedish Alzheimer-focused company BioArctic has entered into a licensing collaboration with Novartis regarding a technology aimed at enhancing efficient drug de...
-
Advancing Drug Discovery by Combining Complex In-Vitro Models with AI-Powered 3D/4D Image Analysis
Free webinar organized by ZEISS.
-
Superconductor technology: Contactless working in the laboratory of the future
Automated filling and weighing of freeze-dry containers in the cleanroom with SupraMotion from Festo
-
Pneumatics Makes a Technological Leap with Piezo
The first high-precision proportional valve terminal VTEP opens up new application areas
-
Positive EMA Decision for BioArctic's New Drug Candidate
Bioarctic's drug candidate for multiple system atrophy, exidavnemab, is recommended to be classified as an orphan drug, according to the European Medicines Agency (EMA).
-
Getinge and Neobiomics received Swecare's export awards
Two companies received awards during Swecare's annual conference.
-
US Health Secretary Kennedy dismisses all vaccine experts – assembles new committee
Robert F. Kennedy Jr. has dismissed all 17 members of the CDC’s vaccine advisory panel. A new group of experts will be appointed directly by the Health Secretar...
-
The top five most expensive drugs in 2025
New advanced therapeutic medicines are reaching the market, but their price tags remain exceptionally high. This year’s ranking of the most expensive drugs in t...
-
Cost-efficient development of laboratory devices
8 ways to optimise development costs and speed up processes
-
Large study on milk: Risky for women but not for men
The risk of ischemic heart disease (IHD) and acute myocardial infarction (MI) increased for women with milk intake levels higher than 2 glasses per day, while n...
BREAKING